Efficacy of selection criteria for ovarian reserve screening using the clomiphene citrate challenge test in a tertiary fertility center population.
OBJECTIVE
To examine selection criteria for ovarian reserve screening.


METHODS
Retrospective study.


METHODS
Two hundred nineteen women underwent testing for ovarian reserve for woman's age > 35 years, any age with unexplained infertility, one ovary, or a poor response to hMG.


METHODS
Clomiphene citrate challenge test.


METHODS
Frequency of abnormal ovarian reserve screening, menstrual cycle parameters, response to hMG, and pregnancy outcome by screening criteria.


RESULTS
One hundred eighty-four (84.0%) women had a normal ovarian reserve screening test; 35 (16.0%) had an abnormal ovarian reserve screening test. Twenty-six had abnormal ovarian reserve screening when screened by age, 14 for unexplained infertility, 5 for poor response to hMG, and 6 for one ovary. Fifteen women with abnormal ovarian reserve screening had more than one indication for screening. For women attempting pregnancy (n = 182), 49 of 148 (33.1%) with normal ovarian reserve screening became pregnant compared with 2 of 34 (5.9%) with abnormal ovarian reserve screening. Within each screening category, women with abnormal ovarian reserve had menstrual cycle parameters associated with a short follicular phase, required more hMG, and responded poorly to hMG.


CONCLUSIONS
One of six women undergoing ovarian reserve screening had an abnormal test, which was associated a poor reproductive outcome. Age was the most important single criteria. Selected ovarian reserve screening is simple and inexpensive and should be offered to all fertility patients meeting the specific screening criteria listed above.
Hofmann
G E
GE
Department of Obstetrics and Gynecology, Bethesda Hospital, Cincinnati, Ohio 45206, USA.
Sosnowski
J
J
Scott
R T
RT
Thie
J
J
D000328:Adult; D000367:Age Factors; D000554:Ambulatory Care Facilities; D002996:Clomiphene; D005260:Female; D005298:Fertility; D005498:Follicular Phase; D006728:Hormones / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy / Q000517:prevention & control*; D008403:Mass Screening; D008596:Menotropins / Q000627:therapeutic use; D008597:Menstrual Cycle / Q000097:blood; D010053:Ovary / Q000502:physiology*; D018579:Patient Selection; D011247:Pregnancy; D018873:Pregnancy Rate; D012189:Retrospective Studies
D006728:Hormones; D002996:Clomiphene; D008596:Menotropins